New combo aims to boost cancer-killing radiation in hard-to-treat tumors
NCT ID NCT05178693
First seen Nov 25, 2025 · Last updated Jun 16, 2026 · Updated 29 times
Summary
This early-stage study tests whether taking a 5-day course of the drug ASTX727 before standard Lutathera radiation therapy can help the radiation target cancer cells more effectively. About 27 adults with metastatic neuroendocrine tumors will receive the combination. The goal is to see if the priming drug can turn on a receptor that makes cancer cells more visible to the radiation, potentially improving treatment response while monitoring side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hammersmith Hospital
RECRUITINGLondon, London, City of, W12 0HS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.